Skip to main content
Premium Trial:

Request an Annual Quote

CAP Accredits CardioDx's Laboratory

NEW YORK (GenomeWeb News) – CardioDx today said that its laboratory in Palo Alto, Calif., has been accredited by the College of American Pathologists.

The company offers the Corus CAD gene expression test for evaluating patients with signs and symptoms of obstructive coronary artery disease through the laboratory, which is also CLIA certified and licensed by the State of New York.

Late last month, CardioDx announced a deal with Core Diagnostics India to offer Corus CAD in India. Samples will be analyzed at CardioDx's lab.

In addition, the company raised $58 million last summer to support commercialization of the test.

As part of the CAP accreditation process, inspectors examine the laboratory's records, quality control procedures, equipment, facilities, safety program, and overall lab management to ensure they meet CAP requirements.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.